[
  {
    "ts": null,
    "headline": "Why Amgen Stock Edged Past the Market on Thursday",
    "summary": "The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.",
    "url": "https://finnhub.io/api/news?id=a21daba9bb6dbf7c6cb18fbc9b45b9468b20955d8c7006e39e95a18a5fb8eaa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763073387,
      "headline": "Why Amgen Stock Edged Past the Market on Thursday",
      "id": 137476991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.",
      "url": "https://finnhub.io/api/news?id=a21daba9bb6dbf7c6cb18fbc9b45b9468b20955d8c7006e39e95a18a5fb8eaa5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Shows Confidence in Amgen",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]",
    "url": "https://finnhub.io/api/news?id=18f3f3396e417563a6dfe380e1cfdde97f847044d1b8477ccc82699af66168ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763053783,
      "headline": "Jim Cramer Shows Confidence in Amgen",
      "id": 137470097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]",
      "url": "https://finnhub.io/api/news?id=18f3f3396e417563a6dfe380e1cfdde97f847044d1b8477ccc82699af66168ee"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]",
    "url": "https://finnhub.io/api/news?id=429de2192c820bae02d8a2fec68426cdf89560f4a44b17a7a14714bc298b39aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763053781,
      "headline": "Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”",
      "id": 137470098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]",
      "url": "https://finnhub.io/api/news?id=429de2192c820bae02d8a2fec68426cdf89560f4a44b17a7a14714bc298b39aa"
    }
  },
  {
    "ts": null,
    "headline": "2 Supercharged Dividend Stocks to Buy Now",
    "summary": "Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.",
    "url": "https://finnhub.io/api/news?id=0419b04da5522574d1766fa98aa81146e58f79468916dd893f847055fc9d3f8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763046420,
      "headline": "2 Supercharged Dividend Stocks to Buy Now",
      "id": 137469206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.",
      "url": "https://finnhub.io/api/news?id=0419b04da5522574d1766fa98aa81146e58f79468916dd893f847055fc9d3f8f"
    }
  },
  {
    "ts": null,
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763045138,
      "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "id": 137468541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0"
    }
  },
  {
    "ts": null,
    "headline": "Cramer's Stop Trading: Amgen",
    "summary": "Jim Cramer breaks down why he's keeping an eye on shares of Amgen.",
    "url": "https://finnhub.io/api/news?id=ef548ac357ec7494a5820b8f3ae08c263e535495c038bb93973b6e2408639486",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763028841,
      "headline": "Cramer's Stop Trading: Amgen",
      "id": 137469781,
      "image": "https://image.cnbcfm.com/api/v1/image/108225469-17630462471763046243-42533808103-1080pnbcnews.jpg?v=1763046246&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Jim Cramer breaks down why he's keeping an eye on shares of Amgen.",
      "url": "https://finnhub.io/api/news?id=ef548ac357ec7494a5820b8f3ae08c263e535495c038bb93973b6e2408639486"
    }
  },
  {
    "ts": null,
    "headline": "Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025?",
    "summary": "Thinking about whether Amgen is a smart buy at today's prices? You are not alone, especially if you are trying to figure out if the current stock price reflects true value or hype. Amgen's share price has surged recently, up 5.1% in the last week and 15.0% over the past month, with year-to-date returns sitting at an impressive 29.7%. Part of this momentum can be traced to news around major pipeline drug approvals and fresh partnerships that have caught investor attention. Ongoing discussions...",
    "url": "https://finnhub.io/api/news?id=a5d9664aa765cf9d93a9402e2c2b95881cc6e1eaa88569e05142cde97af901e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763003799,
      "headline": "Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025?",
      "id": 137467004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Thinking about whether Amgen is a smart buy at today's prices? You are not alone, especially if you are trying to figure out if the current stock price reflects true value or hype. Amgen's share price has surged recently, up 5.1% in the last week and 15.0% over the past month, with year-to-date returns sitting at an impressive 29.7%. Part of this momentum can be traced to news around major pipeline drug approvals and fresh partnerships that have caught investor attention. Ongoing discussions...",
      "url": "https://finnhub.io/api/news?id=a5d9664aa765cf9d93a9402e2c2b95881cc6e1eaa88569e05142cde97af901e9"
    }
  }
]